Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 407-560-9 | CAS number: 107934-68-9 CAF
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Skin sensitisation (equivalent to OECD 406): not sensitising
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 7 May - 1 Jun 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Also in accordance with GLP principles.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Version / remarks:
- adopted 19. Sept. 1984
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Test was done before LLNA as first-choice method for in-vivo testing was set into force.
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: D. Hall, Newchurch, Staffordshire, England
- Age at study initiation: 6 to 7 weeks of age
- Weight at study initiation: 327 - 389 g
- Housing: in groups of ten in suspended cages with wire mesh floors
- Diet: vitamin C-enriched guinea pig diet F.D.1., ad libitum; hay was given weekly
- Water: ad libitum
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21
- Humidity (%): 30-70
- Air changes (per hr): approximately 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 7 May To 01 June 1991 - Route:
- intradermal and epicutaneous
- Vehicle:
- other: Alembicol D
- Concentration / amount:
- Induction: intradermal - 2.5% w/w; epicutaneous - 70% w/w
Challenge: epicutaneous - 25 and 50% w/w - Route:
- epicutaneous, semiocclusive
- Vehicle:
- other: Alembicol D
- Concentration / amount:
- Induction: intradermal - 2.5% w/w; epicutaneous - 70% w/w
Challenge: epicutaneous - 25 and 50% w/w - No. of animals per dose:
- 10 (controls), 20 (in test group)
- Details on study design:
- RANGE FINDING TESTS: The intradermal and topical irritancy of a range of dilutions of T-4113 was investigated to identify where possible (a) irritant test concentrations suitable for induction phase of the main study and (b) non-irritant concentrations by the topical route of administration for the challenge phase. Concentration ranges tested in two animals each were: intradermal - 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 7.5, 10.0% (w/w); topical - 10, 30, 50, 70% (w/w)
MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2 (intradermal and epicutaneous, respectively)
- Exposure period: single intradermal injection and 48 hours topical application
- Test groups:
Intradermal - 3 pairs of injections: (1) a 1:1 mixture (v/v) Freund's Complete adjuvant (FCA)/water; (2) test substance in Alembicol D; (3) test substance in a 1:1 mixture of Freund's complete adjuvant and Alembicol D
Epicutaneous - test substance in Alembicol D
- Control group:
Intradermal - 3 pairs of injections: (1) a 1:1 mixture (v/v) FCA/water; (2) Alembicol D; (3) 1:1 mixture Freund's Complete adjuvant and Alembicol D
Epicutaneous - Alembicol D
- Site: scapular region, intradermal and epicutaneous
- Frequency of applications: every 7 days
- Duration: Days 0-9
- Concentrations: intradermal 2.5% w/w, epicutaneous 70% w/w
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 21
- Exposure period: 24 hours
- Test groups: test substance at 25 and 50% w/w in Alembicol D
- Control group: test substance at 25 and 50% w/w in Alembicol D
- Site: anterior and posterior site on the left flank
- Concentrations: 25 and 50% w/w
- Evaluation (hr after challenge): 24, 48 and 72 hours
OTHER:
Justification for choice of vehicle: Alembicol D# is a product of coconut oil. By fractionating the fatty acids of coconut oil and re-esterifying with glycerine, a Medium Chain Triglyceride (MCT) Oil is produced. Alembicol D is such an oil. It is advantageous in this type of test in that it is stable, has a low viscosity and surface tension and is easily absorbed into the skin. These properties make it ideal as a vehicle for intradermal injections and topical applications. - Positive control substance(s):
- yes
- Remarks:
- Formalin (checked periodically)
- Positive control results:
- Formalin is used as positive control and checked regularly to test the stability of the assay;
concentrations used: intradermal - 0.05 -0.1%; epicutaneous - 5 -10%; challenge - 1 -5%; usually 50 - 100% of the tested animals showed sensitizing reactions in all studies conducted - Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- other: 3rd reading
- Hours after challenge:
- 72
- Group:
- negative control
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- other: 3rd reading
- Hours after challenge:
- 72
- Group:
- test chemical
- Dose level:
- Challenge 25 and 50%
- No. with + reactions:
- 0
- Total no. in group:
- 20
- Clinical observations:
- Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
- Reading:
- 1st reading
- Group:
- positive control
- Dose level:
- Challenge 5% and 1%
- No. with + reactions:
- 10
- Total no. in group:
- 10
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- In this adjuvant type guinea pig test method for skin sensitisation according to OECD 406 guideline and GLP principles, the substance did not produce evidence of skin sensitization in any of the twenty test animals.
- Executive summary:
Assessment of the skin sensitization potential of the test substance using the guinea-pig according to OECD 406 guideline and GLP principles. No signs of ill health or toxicity were recorded.
Induction:
Intradermal injections: Necrosis was recorded at sites receiving FCA in test and control animals. Slight irritation was seen in test animals at sites receiving the 2.5% test substance in Alembicol D and similar signs of irritation were observed in control animals receiving Alembicol D.
Topical application: Slight erythema was observed in test animals following topical application with the 70% test substance in Alembicol D and similar signs of irritation were seen in the controls.
Challenge:
There were no dermal reaction seen in any of the test or control animals.
Based on the results, the substance did not produce evidence of skin sensitization in any of the twenty test animals.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Skin sensitisation
The skin sensitising potential of 4,4'-(9H-fluoren-9-ylidene)bis(2-chloroaniline) (CAS 107934-68-9) was evaluated in a guinea pig maximisation test performed according to OECD 406 (Parcell and Healing, 1991). 20 female guinea pigs in the test group and 10 females in the control group were induced by intradermal and epicutaneous exposure to the test substance. Intradermal induction was performed with 2.5% test solution, and epicutaneous induction was performed with 70% test solution. Skin reactions (necrosis) were observed after intradermal induction at application sites receiving FCA. In addition, slight irritation was observed at sites receiving 2.5% (intradermal induction) test substance in Alembicol D. Slight erythema were observed following topical induction. The challenge was performed by open epicutaneous exposure to a 25% and 50% formulation of test substance in Alembicol D. The animals in the treatment group and the control group did not show any signs of a sensitising effect at the reading time points (24, 48, and 72 h after challenge). In conclusion 0/10 and 0/20 animals of the control and test group showed any reaction after the challenge period, thus indicating that the test substance is not sensitising under the conditions of the test.
Justification for selection of skin sensitisation endpoint:
There is only one study available.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
No data available.
Justification for selection of respiratory sensitisation endpoint:
The study is not required according to Annex VII - X of Regulation (EC) No 1907/2006.
Justification for classification or non-classification
The available data on skin sensitisation of 4,4´-(9H-fluoren-9 -ylidene)bis(2 -chloroaniline) do not meet the criteria for classification according to Regulation (EC) 1272/2008, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
